Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on January 21, 2021. The report addresses a corporate governance event regarding the transfer of the company's stock listing from the NYSE American to the Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing status and does not contain financial performance data.
Material Changes
- Listing Transfer: The Company received approval to list on the Nasdaq Global Market under the symbol "CRMD".
- Trading Transition: Common stock will begin trading on Nasdaq on February 2, 2021.
- Previous Exchange: Shares will continue to trade on the NYSE American until the market close on February 1, 2021.
Outlook and Management Commentary
Management, represented by CEO Khoso Baluch, confirmed the transfer of listing. The filing incorporates a press release (Exhibit 99.1) detailing the announcement. No specific financial guidance, risk factors, or contingencies related to operations were disclosed in this specific document.
Investor Verification Checklist
- Verify the exact start date of trading on Nasdaq (February 2, 2021).
- Confirm the final trading day on NYSE American (February 1, 2021).
- Review the full text of the press release filed as Exhibit 99.1 for additional context.
- Check subsequent filings for financial data, as this 8-K contains no financial metrics.